Electrifying your workout can boost muscles’ mass and strength, study finds
If building strength and muscle mass is part of your New Year’s Resolution, you may want to add a new routine to your workout.
Read More
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight advancements in lung cancer detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA. A live webcast of the event will be accessible by visiting the “Events and Present
Instem Introduces Cloud-Hosted Non-GLP Pathology Module for Provantis
STONE, England–(BUSINESS WIRE)–Instem, a global leader in IT solutions for life sciences, has announced the launch of its new Non-GLP Pathology Module for Provantis, the market share-leading in vivo preclinical study management solution. Trusted by a wide user base including pathologists, Provantis streamlines workflows and enables efficient data management. This new module is designed to eliminate inefficiencies and modernize pathology workflows. This cloud-hosted solution simplifies data en
Dementia diagnosis: How long do patients really live?
The average life expectancy of people diagnosed with dementia ranges from nine years at age 60 to 4.5 years at age 85 for women and from 6.5 to just over two years, respectively, in men, finds a systematic review of the latest evidence in The BMJ.
Anthem Blue Cross Pledges $10 Million in Support of Southern California Communities Affected by Wildfires
INDIANAPOLIS–(BUSINESS WIRE)–For more than eight decades, Anthem Blue Cross has been deeply connected to California, placing people at the center of our work. Our enduring commitment reflects our shared health journey with Californians, and we recognize the profound impact of disasters on the well-being of our associates, members, care providers, and communities. As a lifetime trusted health partner, our family of companies is dedicated to delivering essential resources and relief, upholding
Suicidal behavior found to be more common among construction workers
A study conducted at the University of Gothenburg shows that male construction workers have a 50% higher risk of suicide attempts and suicide. The findings confirm that suicidal behavior is more common among men in professions with low educational requirements.
Study finds 1 in 4 older U.S. veterans report cardiovascular disease diagnosis
One in four older U.S. veterans report being diagnosed with cardiovascular disease (CVD) in their lifetime, according to a study published online Dec. 18 in PLOS Mental Health.
Mortality lower with lung volume reduction surgery in emphysema, study finds
For patients with advanced emphysema, endobronchial valve placement (EBV) is associated with higher mortality and morbidity compared with lung volume reduction surgery (LVRS), according to a study presented at the annual meeting of The Society of Thoracic Surgeons, held from Jan. 24 to 26 in Los Angeles.
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share. Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate th